Pricing and Reimbursement Application Tracker
Login
Search
durvalumab (Imfinzi®)
Application Details
HSE Application ID
HSE100102
HTA Number
26018
HTA Link
https://www.ncpe.ie/durvalumab-imfinzi-hta-id-26018/
Drug
durvalumab
Brand
Imfinzi®
Applicant
AstraZeneca
Indication Applied For
Durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR).
Application Date
09/04/2026
Marketing Authorisation Date
26/07/2024
Application Status
Awaiting Proposal from Applicant
02/07/2026
Applicant Meeting Held with CPU
02/07/2026
Rapid Review Completed
15/05/2026
Rapid Review Commissioned
10/04/2026
Pricing and Reimbursement Application Complete
09/04/2026
New Search
Status
Pricing and Reimbursement Application Complete
Rapid Review Commissioned
Rapid Review Completed
Applicant Meeting Held with CPU
Awaiting Proposal from Applicant
Proposal from Applicant Under Review
Full Health Technology Assessment Commissioned by HSE
NCPE Assessment Completed
HSE Drugs Group Review Pending
Reviewed by HSE Drugs Group
HSE Rare Disease Technology Review Committee - Review Requested
HSE Rare Disease Technology Review Committee - Review Received
Further Information Requested by HSE Drugs Group
Reviewed by HSE Senior Leadership Team
Managed Access Protocol (MAP) Commissioned
Proposed HSE Decision Issued to Applicant
Applicant Representations Received
HSE Decision Issued to Applicant
Application On Hold at the Request of Applicant
Application Withdrawn at the Request of Applicant
Application on Hold as Agreed by HSE and Applicant
HSE Approval Letter Issued to Applicant
Full Health Technology Assessment Submitted to NCPE
Delete Application
×
Are you sure you want to delete this Application?
Once it's deleted it cannot be retrieved.
Remove Status and Date
×
Are you sure you want to delete this?